Resilience acquires Ology Bioservices

By The Science Advisory Board staff writers

Resilience has purchased biologic drug substance manufacturing firm Ology Bioservices (Ology Bio); terms of the deal were not disclosed.

For Resilience, the deal adds 300 skilled employees, as well as over 200,000 sq ft of manufacturing, office, process development, and quality assurance/control space across locations in Florida, California, and Maryland. Additional expansion projects are also underway, according to the company.

Alachua, FL-based Ology Bio develops and manufactures drugs and biologics for commercial customers, as well as the U.S. government. It has been awarded more than $1.8 billion in government contracts, including a $37 million contract in November to develop an anti-COVID-19 monoclonal antibody cocktail, according to Resilience.

Resilience customers can utilize Ology Bio's services, including regulatory support from preclinical development through licensure, clinical trial operations support, bioanalytical testing, as well as current good manufacturing practice manufacturing up to Biosafety Level 3, the company said. Ology Bio can manufacture cell and gene therapies, live viral vaccines and vectors, oncolytic viruses, plasmids, and monoclonal antibodies.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?